The efficacy of cefdinir in acute bacterial rhinosinusitis

Expert Opinion on Pharmacotherapy

Volumn 7, Issue 8, 2006, Pages 1075-1083

  Hadley, James A ^a,b  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b University Otolaryngology Associates   (United States)

Author keywords

Acute bacterial rhinosinusitis; Cefdinir; Cephalosporins; Rhinosinusitis; Sinusitis

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; AZITHROMYCIN; CEFDINIR; CEFPODOXIME; CEFPROZIL; CEFUROXIME; CEFUROXIME AXETIL; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; GATIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; OXYTETRACYCLINE; PENICILLIN G; TETRACYCLINE DERIVATIVE;

ACUTE DISEASE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL INFECTION; BACTERICIDAL ACTIVITY; CLINICAL TRIAL; DIARRHEA; DRUG ABSORPTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG PREFERENCE; DRUG TOLERABILITY; HAEMOPHILUS INFLUENZAE; HUMAN; INSOMNIA; LUNG PARENCHYMA; MORAXELLA CATARRHALIS; PATIENT COMPLIANCE; PRACTICE GUIDELINE; RHINOSINUSITIS; STREPTOCOCCUS PNEUMONIAE; TISSUE DISTRIBUTION;

ACUTE DISEASE; ADMINISTRATION, ORAL; ANTI-INFECTIVE AGENTS; CEPHALOSPORINS; DRUG ADMINISTRATION SCHEDULE; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE; HUMANS; MORAXELLA (BRANHAMELLA) CATARRHALIS; MORAXELLACEAE INFECTIONS; PNEUMOCOCCAL INFECTIONS; RANDOMIZED CONTROLLED TRIALS; SINUSITIS; STREPTOCOCCUS PNEUMONIAE;

EID: 33745452449     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.7.8.1075     Document Type: Article

References (56)

1. GUAY DR: Cefdinir: an advanced-generation, broad-spectrum oral cephalosporin. Clin. Ther. (2002) 24:473-489.
2. PERRY CM, SCOTT LJ: Cefdinir. A review of its use in the management of mild-to-moderate bacterial infections. Drugs (2004) 64:1433-1464.
3. GWALTNEY JM JR, SAVOLAINEN S, RIVAS P et al.: Comparative effectiveness and safety of cefdinir and amoxicillin-clavulanate in treatment of acute community-acquired bacterial sinusitis. Antimicrob. Agents Chemother. (1997) 41:1517-1520.
4. HENRY DC, KAPRAL D, BUSMAN TA, PARIS MM: Cefdinir versus levofloxacin in patients with acute rhinosinusitis of presumed bacterial etiology: a multicenter, randomized, double-blind study. Clin. Ther. (2004) 26:2026-2033.
5. ANON JB, JACOBS MR, POOLE MD et al.: Antimicrobial treatment guidelines for acute bacterial rhinosinusitis. Otolaryngol. Head Neck Surg. (2004) 130(1 Suppl.):1-45.
6. RAY NF, BARANIUK JN, THAMER M et al: Healthcare expenditures for sinusitis in 1996: contributions of asthma, rhinitis, and other airway disorders. J. Allergy Clin. Immunol. (1999) 103:408-414.
7. STEFFANSON P, JACOVIDES A, JABLONICKY P, SEDANI S, STALEY H: Cefuroxime axetil versus clarithromycin in the treatment of acute maxillary sinusitis. Rhinology (1998) 36:173-178.
8. DURR DG, DESROSIERS MY, DASSA C: Impact of rhinosinusitis in health care delivery: the Quebec experience. J. Otolaryngol. (2001) 30:93-97.
9. SENIOR BA, GLAZE C, BENNINGER MS: Use of the Rhinosinusitis Disability Index (RSDI) in rhinologic disease. Am. J. Rhinol. (2001) 15:15-20.
10. BERG O, CARENFELT C, RYSTEDT C, ÄNGGÅRD A: Occurrence of asymptomatic sinusitis in common cold and other acute ENT-infections. Rhinology (1986) 24:233-235.
11. WALD ER, GUERRA N, BYERS C: Upper respiratory tract infections in young children: duration and frequency of complications. Pediatrics (1991) 87:129-133.
12. GWALTNEY JM: Management update of acute bacterial rhinosinusitis and the use of cefdinir. Otolaryngol. Head Neck Surg. (2002) 127:S24-S29.
13. JORISSEN M, HERMANS R, BERTRAND B, ELOY PH: Anatomical variations and sinusitis. Acta. Otorhinolaryngologica. Belg. (1997) 51:219-226.
14. AMERICAN ACADEMY OF PEDIATRICS SUBCOMMITTEE ON MANAGEMENT OF SINUSITIS AND COMMITTEE ON QUALITY IMPROVEMENT: Clinical practice guideline: management of sinusitis. Pediatrics (2001) 108:798-808.
15. STEELE RW: Chronic sinusitis in children. Clin. Pediatr. (2005) 44:465-471.
16. HICKNER JM, BARTLETT JG, BFSSER RE, GONZALES R, HOFFMAN JR, SANDE MA: Principles of appropriate antibiotic use for acute rhinosinusitis: background. Ann. Intern. Med. (2001) 134:498-505.
17. LACROIX JS, RICCHETTI A, LEW D et al.: Symptoms and clinical and radiological signs predicting the presence of pathogenic bacteria in acute rhinosinusitis. Acta Otolaryngol. (2002) 122:192-196.
18. SNOW V, MOTTUR PILSON C, HICKNER JM FOR THE AMERICAN COLLEGE OF PHYSICIANS-AMERICAN SOCIETY OF INTERNAL MEDICINE: Principles of appropriate antibiotic use for acute sinusitis in adults. Ann. Intern. Med. (2001) 134:495-497.
19. GWALTNEY JM JR, WIESINGER BA, PATRIE JT: Acute community-acquired bacterial sinusitis: the value of antimicrobial treatment and the natural history. Clin. Infect Dis. (2004) 38:227-233.
20. BLOMGREN K, ALHO OP, ERTAMA L et al.: Acute sinusitis: Finnish clinical practice guidelines. Scand. J. Infect. Dis. (2005) 37:245-250.
21. TALBOT GH, KENNEDY DW, SCHELD WM, GRANITO K; ENDOSCOPY STUDY GROUP: Rigid nasal endoscopy versus sinus puncture and aspiration for microbiologic documentation of acute bacterial maxillary sinusitis. Clin. Infect. Dis. (2001) 33:1668-1675.
22. BENNINGER MS, APPELBAUM PC, DENNENY JC, OSGUTHORPE DJ, STANKIEWICZ JA: Maxillary sinus puncture and culture in the diagnosis of acute rhinosinusitis: the case for pursuing alternative culture methods. Otolaryngol. Head Neck Surg. (2002) 127:7-12.
23. JONIAU S, VLAMINCK S, VAN LANDUYT H, KUHWEIDE R, DICK C: Microbiology of sinus puncture versus middle meatal aspiration in acute bacterial maxillary sinusitis. Am. J. Rhinol. (2005) 19:135-140.
24. BENNINGER MS, PAYNE SC, FERGUSON BJ, AHMAD N, HADLEY J: Endoscopically directed middle meatal cultures versus maxillary sinus taps in acute bacterial rhinosinusitis: a meta analysis. Otolaryngol. Head Neck Surg. (2006) 134:3-9.
25. DESROSIERS M, FRENKIEL S, HAMID QA et al.: Acute bacterial sinusitis in adults: management in the primary care setting. J. Otolaryngol. (2002) 31(Suppl. 2):2S2-2S14.
26. SOKOL W. Epidemiology of sinusitis in the primary care setting: results from the 1999-2000 respiratory surveillance program. Am. J. Med. (2001) 111 (Suppl. 9A): 19S-24S.
27. TAGHIZADEH F, HADLEY JA, OSGUTHORPE JD: Pharmacological treatments for rhinosinusitis. Expert Opin. Pharmacother. (2002) 3:305-313.
28. YOUNIS RT, LAZAR RH, BUSTILLO A, ANAND VK: Orbital infection as a complication of sinusitis: are diagnostic and treatment trends changing? Ear Nose Throat J. (2002) 81:771-775.
29. ONG YK, TAN HK: Suppurative intracranial complications of sinusitis in children. Int. J. Pediatr. Otorhinolaryngol. (2002) 66:49.
30. HERRMANN BW, FORSEN JW Jr: Simultaneous intracranial and orbital complications of acute rhinosinusitis in children. Int. J. Pediatr. Otorhinolaryngol. (2004) 68:619-625.
31. NATSIS K, KARABATAKIS V, TSIKARAS P, CHATZIBALIS T, STANGOS A, STANGOS N: Frontal sinus anatomical variations with potential consequences for the orbit. Study on cadavers. Morphologie (2004) 88:35-38.
32. GONZALES R, STEINER JF, SANDE MA: Antibiotic prescribing for adults with colds, upper respiratory tract infections, and bronchitis by ambulatory care physicians. JAMA (1997) 278:901-904.
33. DOHAR J, CANTÓN R. COHEN R, FARRELL DJ, FELMINGHAM D: Activity of telithromycin and comparators against bacterial pathogens isolated from 1,336 patients with clinically diagnosed acute sinusitis. Ann. Clin. Microbiol. Antimicrob. (2004) 3:15-21.
34. BROWN SD, RYBAK MJ: Antimicrobial susceptibility of Streptococcus pneumoniae, Streptococcus pyogenes and Haemophilus influenzae collected from patients across the USA, in 2001-2002, as part of the PROTEKT US study. J. Antimicrob. Chemother. (2004) 54:(Suppl. 1):i7-i15.
35. FELMINGHAM D, REINERT RR, HIRAKATA Y, RODLOFF A: Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and comparative in vitro activity of the ketolide, telithromycin. J. Antimicrob. Chemother. (2002) 50(Suppl. S1):25-37.
36. SADER HS, FRITSCHE TR, MUTNICK AH, JONES RN: Contemporary evaluation of the in vitro activity and spectrum of cefdinir compared with other orally administered antimicrobials tested against common respiratory tract pathogens (2001-2002). Diagn. Microbiol. Infect. Dis. (2003) 47:515-525.
37. GRANIZO JJ, AGUILAR L, CASAL J, GARCIA-REY C, DAL-RE R, BAQUERO F: Streptococcus pneumoniae resistance to erythromycin and penicillin in relation to macrolide and beta-lactam consumption in Spain (1979-1997). J. Antimicrob. Chemother. (2000) 46:767-773.
38. ALBRICH WC, MONNET DL, HARBARTH S: Antibiotic selection pressure and resistance in Streptococcus pneumoniae and Streptococcus pyogenes. Emerg. Infect. Dis. (2004) 10:514-517.
39. BARKAI G, GREENBERG D, GIVON-LAVI N, DREIFUSS E, VARDY D, DAGAN R: Community prescribing and resistant Streptococcus pneumoniae. Emerg. Infect. Dis. (2005) 11:829-837.
40. MCCAIG LF, BESSER RE, HUGHES JM: Antimicrobial drug prescriptions in ambulatory care settings, United States, 1992-2000. Emerg. Infect. Dis. (2003) 9:432-437.
41. HOBAN D, FELMINGHAM D: The PROTEKT surveillance study: antimicrobial susceptibility of Haemophilus influenzae and Moraxella catarrhalis from community-acquired respiratory tract infection. J. Antimicrob. Chemother. (2002) 50(Suppl. S1):49-59.
42. CHATTERJEE A, MOLAND ES, THOMSON KS: Cefnidir: an oral alternative to parenteral cephems. Diagn. Microbiol. Infect. Dis. (2005) 51:259-264.
43. NATIONAL COMMITTEE FOR CLINICAL LABORATORY STANDARDS (NCCLS): Performance standards for antimicrobial susceptibility testing. Supplemental tables. M100-S13. NCCLS, Wayne, PA (2003).
44. CHEN DK, MCGEER A, DE AZAVEDO JC, LOW DE: Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N. Engl. J. Med. (1999) 341:233-239.
45. ABBOTT LABORATORIES: Omnicef® (cefdinir) prescribing information. Abbott Laboratories, North Chicago (IL) USA (2004).
46. RICHER M, ALLARD S, MANSEAU L, VALLEE F, PAK R, LEBEL M: Suction-induced blister fluid penetration of cefdinir in healthy volunteers following ascending oral doses. Antimicrob. Agents Chemother. (1995) 39:1082-1086.
47. STEURER M, SCHENK P: Efficacy and safety of cefdinir in the treatment of maxillary sinusitis. Eur. Arch. Otorhinolaryngol. (2000) 257:140-148.
48. O-LEE T, STEWART CE 4TH, SEERY L, CHURCH CA: Fluoroquinolone-induced arthralgia and myalgia in the treatment of sinusitis. Am. J. Rhinol. (2005) 19:395-399.
49. COHEN JS: Peripheral neuropathy associated with fluoroquinolones. Ann. Pharmacother. (2001) 35:1540-1547.
50. HEDENMALM K, SPIGSET O: Peripheral sensory disturbances related to treatment with fluoroquinolones. J. Antimicrob. Chemother. (1996) 37:831-837.
51. BLOCK SL, BUSMAN TA, PARIS MM, BUKOFZER S: Comparison of five-day cefdinir treatment with ten-day low dose amoxicillin/clavulanate treatment for acute otitis media. Pediatr. Infect. Dis. J. (2004) 23:834-838.
52. BROOK I, GOBER AE: Long-term effects on the nasopharyngeal flora of children following antimicrobial therapy of acute otitis media with cefdinir or amoxycillin-clavulanate. J. Med. Microbiol. (2005) 54:553-556.
53. KARDAS P: Patient compliance with antibiotic treatment for respiratory tract infections. J. Antimicrob. Chemother. (2002) 49:897-903.
54. STEELE RW, THOMAS MP, BEGUE RE: Compliance issues related to the selection of antibiotic suspensions for children. Pediatr. Infect. Dis. J. (2001) 20:1-5.
55. POWERS JL, GOOCH WM 3RD, ODDO LP: Comparison of the palatability of the oral suspension of cefdinir versus amoxicillin/clavulanate potassium, cefprozil and azithromycin in pediatric patients. Pediatr. Infect. Dis. J. (2000) 19(12 Suppl.):S174-S180.
56. KLEIN JA, MCCRACKEN GH: Summary: role of a new oral cephalosporin, cefdinir, for therapy of infections of infants and children. Pediatr. Infect. Dis. J. (2000) 19:S181-S182.